Skip to main content

Table 2 Comparison of chromosomal abnormalities * seen in patients with and without CNS involvement

From: Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults

Variables

Total (n = 378)

Patients with CNS involvement (n = 19)

Patients without CNS involvement (n = 359)

Pvalue

Number (%) of patients

Karyotype †

   

0.378

Favorable

50

3(15.8)

47(13.1)

 

Intermediate

264

15(78.9)

249(69.4)

 

Unfavorable

64

1(5.3)

63(17.5)

 

t(8;21)

34

1(5.3)

33(9.2)

>0.999

inv(16)

16

2(10.5)

14(3.9)

0.189

11q23 abnormalities

14

4(21.1)

10(2.8)

0.003

-5/5q-‡

1

0(0)

1(0.3)

>0.999

-7/7q-‡

6

0(0)

6(1.7)

>0.999

t(7;11)

4

0(0)

4(1.1)

>0.999

t(6;9)

2

0(0)

2(0.6)

>0.999

+8‡

17

1(5.3)

16(4.5)

0.592

  1. *Three hundred and seventy-eight patients had cytogenetic profiles at diagnosis. The remaining 17 patients did not have data of cytogenetic profiles because of inadequate metaphase cells for alalysis.
  2. †Favorable, t(8;21), inv (16); unfavorable, -7, del(7q), -5, del(5q), 3q abnormality, complex abnormalities; Intermediate, normal karyotype and other abnormalities.
  3. ‡Includes only simple chromosomal abnormalities with 2 or fewer changes, but not those with complex abnormalities with 3 or more aberrations.
  4. Abbreviation: CNS central nervous system.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us